Genomic editing technology has been developed since 2010 through the use of some techniques, such as the clustered regularly interspaced short palindromic repeat (CRISPR) DNA sequences/CRISPR-associated (Cas) type-9 method, or through genetic manipulation tools derived from host response systems from some microbes (e.g., bacteria) against plasmids and viruses. The introduction of the CRISPR/Cas9 method as a genome-editing instrument represented an important step in the advancement of the genome-editing method thanks to the ease and effectiveness of use as well as the great adaptability to different biomedical areas. This paragraph will discuss all conceived technologies and new perspectives that can be applied in treating some associated genetic disorders, such as cardiovascular diseases, metabolic diseases, inflammatory diseases, and tumors by means of reversible and modulating control of gene expression epigenetics using genetic editing techniques.

Prospective Advances in Genome Editing Investigation

Isola G.
Primo
Writing – Review & Editing
2023-01-01

Abstract

Genomic editing technology has been developed since 2010 through the use of some techniques, such as the clustered regularly interspaced short palindromic repeat (CRISPR) DNA sequences/CRISPR-associated (Cas) type-9 method, or through genetic manipulation tools derived from host response systems from some microbes (e.g., bacteria) against plasmids and viruses. The introduction of the CRISPR/Cas9 method as a genome-editing instrument represented an important step in the advancement of the genome-editing method thanks to the ease and effectiveness of use as well as the great adaptability to different biomedical areas. This paragraph will discuss all conceived technologies and new perspectives that can be applied in treating some associated genetic disorders, such as cardiovascular diseases, metabolic diseases, inflammatory diseases, and tumors by means of reversible and modulating control of gene expression epigenetics using genetic editing techniques.
978-981-19-5641-6
978-981-19-5642-3
Cancer
Cardiovascular diseases
CRISPR/Cas9
Epigenetic
Genome editing
Inflammatory diseases
Metabolic diseases
Oral diseases
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/545021
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact